Danaher (NYSE:DHR) Stock Unloaded Rep. Robert Bresnahan, Jr.

Representative Robert Bresnahan, Jr. (R-Pennsylvania) recently sold shares of Danaher Co. (NYSE:DHR). In a filing disclosed on March 27th, the Representative disclosed that they had sold between $15,001 and $50,000 in Danaher stock on February 25th. The trade occurred in the Representative’s “JP MORGAN BROKERAGE ACCOUNT” account.

Representative Robert Bresnahan, Jr. also recently made the following trade(s):

• Purchased $1,001 – $15,000 in shares of Intuit (NASDAQ:INTU) on 3/7/2025.
• Sold $1,001 – $15,000 in shares of Tesla (NASDAQ:TSLA) on 3/6/2025.
• Purchased $1,001 – $15,000 in shares of SEA (NYSE:SE) on 3/5/2025.
• Sold $1,001 – $15,000 in shares of Credo Technology Group (NASDAQ:CRDO) on 3/4/2025.
• Purchased $1,001 – $15,000 in shares of Meta Platforms (NASDAQ:META) on 3/4/2025.
• Purchased $1,001 – $15,000 in shares of Twilio (NYSE:TWLO) on 3/4/2025.
• Sold $15,001 – $50,000 in shares of Alibaba Group (NYSE:BABA) on 3/4/2025.
• Purchased $1,001 – $15,000 in shares of Zoom Video Communications (NASDAQ:ZM) on 3/4/2025.
• Purchased $1,001 – $15,000 in shares of Intel (NASDAQ:INTC) on 3/3/2025.
• Purchased $1,001 – $15,000 in shares of Snowflake (NYSE:SNOW) on 3/3/2025.

Danaher Stock Down 2.1 %

Shares of NYSE:DHR opened at $205.69 on Friday. The firm has a market capitalization of $147.01 billion, a PE ratio of 38.96, a price-to-earnings-growth ratio of 2.66 and a beta of 0.82. The company has a debt-to-equity ratio of 0.31, a quick ratio of 1.05 and a current ratio of 1.40. Danaher Co. has a 52-week low of $196.80 and a 52-week high of $281.70. The firm has a fifty day moving average of $214.57 and a 200 day moving average of $236.64.

Danaher (NYSE:DHR) last announced its quarterly earnings data on Wednesday, January 29th. The conglomerate reported $2.14 EPS for the quarter, meeting the consensus estimate of $2.14. Danaher had a return on equity of 10.82% and a net margin of 16.33%. During the same quarter last year, the firm posted $2.09 EPS. As a group, research analysts anticipate that Danaher Co. will post 7.63 EPS for the current fiscal year.

Danaher Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, April 25th. Stockholders of record on Friday, March 28th will be given a dividend of $0.32 per share. The ex-dividend date is Friday, March 28th. This represents a $1.28 annualized dividend and a dividend yield of 0.62%. This is a boost from Danaher’s previous quarterly dividend of $0.27. Danaher’s dividend payout ratio (DPR) is 24.24%.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the company. Fire Capital Management LLC bought a new position in Danaher in the fourth quarter worth $823,000. DSG Capital Advisors LLC bought a new position in shares of Danaher in the 4th quarter worth about $802,000. Chancellor Financial Group WB LP purchased a new position in Danaher during the 4th quarter valued at about $657,000. 111 Capital purchased a new stake in Danaher in the fourth quarter worth about $1,734,000. Finally, Thoma Capital Management LLC bought a new position in shares of Danaher during the fourth quarter valued at approximately $618,000. Institutional investors own 79.05% of the company’s stock.

Analysts Set New Price Targets

DHR has been the subject of a number of research reports. Robert W. Baird cut their price objective on shares of Danaher from $277.00 to $268.00 and set an “overweight” rating for the company in a research note on Tuesday, January 28th. Bank of America raised Danaher from a “neutral” rating to a “buy” rating and set a $290.00 price objective on the stock in a research note on Friday, December 13th. Citigroup lowered their target price on Danaher from $285.00 to $265.00 and set a “buy” rating for the company in a research note on Thursday, January 30th. StockNews.com lowered Danaher from a “buy” rating to a “hold” rating in a research report on Saturday, December 14th. Finally, JPMorgan Chase & Co. dropped their price objective on Danaher from $310.00 to $300.00 and set an “overweight” rating for the company in a research note on Tuesday, January 28th. Five analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company’s stock. According to MarketBeat.com, Danaher currently has an average rating of “Moderate Buy” and an average price target of $278.24.

Insider Activity

In related news, SVP Brian W. Ellis sold 5,700 shares of the firm’s stock in a transaction that occurred on Thursday, January 30th. The stock was sold at an average price of $224.13, for a total transaction of $1,277,541.00. Following the completion of the transaction, the senior vice president now owns 20,230 shares of the company’s stock, valued at $4,534,149.90. This trade represents a 21.98 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Company insiders own 11.10% of the company’s stock.

About Representative Bresnahan

Rob Bresnahan Jr. (Republican Party) is a member of the U.S. House, representing Pennsylvania’s 8th Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027.

Bresnahan (Republican Party) is running for re-election to the U.S. House to represent Pennsylvania’s 8th Congressional District. He declared candidacy for the 2026 election.

Rob Bresnahan Jr. was born in Kingston, Pennsylvania. He earned a B.S. in business administration, management and operations from the University of Scranton in 2012. His career experience includes working as the chief financial officer and CEO of a family business, an electrical contracting company.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.